The Effect of Delay in Diagnosis and Treatment Process on Recurrence and Progression of Patients with Non- Muscle-Invasive Bladder Cancer During The COVID-19 Pandemic
- 13 December 2022
- journal article
- research article
- Published by Galenos Yayinevi in Üroonkoloji Bülteni
- Vol. 21 (4) , 134-139
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Risk Stratification Tools and Prognostic Models in Non–muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines PanelEuropean Urology Focus, 2020
- Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette–Guérin shortageCurrent Opinion in Urology, 2020
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 UpdateEuropean Urology, 2019
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Early vs delayed radical cystectomy for ‘high‐risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer‐specific survivalBJU International, 2011
- Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic Review of the LiteratureEuropean Urology, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder CarcinomaJournal of Urology, 2003
- Delay and survival in bladder cancerBJU International, 2002
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999